Tela Bio, Inc. (TELA) Stock Price & Analysis
Tela Bio, Inc. (TELA) fell 2.81% to USD 0.69 as of July 25, 2026 at 09:45 UTC, according to Nexqual real-time market data.
TELA last closed at USD 0.71; the session ranged USD 0.69–0.76 on volume of 35,921 shares. Market capitalization is $30.93M, with a 52-week range of USD 0.5–2.14 (NGM). Source: Nexqual, July 25, 2026 at 09:45 UTC.
Key Statistics (as of July 25, 2026 at 09:45 UTC)
| Price | USD 0.69 |
|---|---|
| Change | ▼ 2.81% (down) |
| Previous Close | USD 0.71 |
| Open | USD 0.74 |
| Day Range | USD 0.69 – 0.76 |
| 52-Week Range | USD 0.5 – 2.14 |
| Volume | 35,921 shares |
| Market Cap | $30.93M |
| Exchange | NGM |
Technical Analysis (TELA)
Nexqual's technical model rates TELA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.34 (neutral) |
| vs SMA50 | Below (USD 0.83) |
| MACD | -0.03 (negative) |
Analyst Ratings (TELA)
Wall Street analysts rate TELA "None" based on 5 analysts, with a mean price target of USD 2.25 (range USD 1–3.25), per Nexqual as of July 25, 2026 at 09:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 2.25 |
| High Target | USD 3.25 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (TELA)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.18 |
| Revenue Estimate | $20.01M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.17 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.2 ▲ beat |
| 2025-06-30 | USD -0.22 vs est -0.19 ▼ miss |
Source: Nexqual, July 25, 2026 at 09:45 UTC.
Financials & Fundamentals (TELA)
| Total Revenue | $80.81M |
|---|---|
| Revenue Growth (YoY) | +2.90% |
| Gross Margin | +67.72% |
| Operating Margin | -55.23% |
| Profit Margin | -49.30% |
| ROE | -616.62% |
| Current Ratio | 3.61 |
| Total Cash | $39.54M |
| Total Debt | $57.79M |
| Free Cash Flow | $-17.44M |
Source: Nexqual, July 25, 2026 at 09:45 UTC.
Financial Health Score (TELA)
Nexqual rates Tela Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:45 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 68%, operating -55% |
| Balance Sheet | Mixed — $40M cash vs $58M debt |
| Cash Flow | Weak — FCF negative: -$17M, burning cash |
| Efficiency | Critical — ROE -617%, ROA -28.7% |
Ownership (TELA)
| Insider Ownership | +7.71% |
|---|---|
| Institutional Ownership | +68.86% |
| Shares Outstanding | 44.77M |
| Float | 19.93M |
| Short % of Float | +1.17% |
Source: Nexqual, July 25, 2026 at 09:45 UTC.
Leadership (TELA)
Tela Bio, Inc. is led by Antony Koblish (age 59), Co-founder, CEO & Director, per Nexqual as of July 25, 2026 at 09:45 UTC.
| Co-founder, CEO & Director | Antony Koblish (age 59) |
|---|---|
| President | Jeffrey Blizard (age 56) |
| CFO, Corporate Secretary & COO | Roberto E. Cuca (age 57) |
| Chief Technology Officer | Paul Talmo (age 58) |
| Senior Vice President of Human Resources | Jennifer Lou Armstrong (age 55) |
Major Backers & Investors (TELA)
Notable institutional backers of Tela Bio, Inc. include Essex Woodlands Management Inc., Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, according to Nexqual as of July 25, 2026 at 09:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 17.23% |
| Nantahala Capital Management, LLC | 11.49% |
| Stonepine Capital Management, LLC | 5.85% |
| SilverArc Capital Management, LLC | 5.05% |
| DAFNA Capital Management, LLC | 3.22% |
| Perkins Capital Management, Inc. | 3.17% |
| UBS Group AG | 2.37% |
| Citigroup Inc. | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.88% |
Source: Nexqual, July 25, 2026 at 09:45 UTC.
From Tela Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and medical affairs functions to drive physician awareness, education and clinical understanding of our products, and utilizing engagement analytics to support further product development and enhancement opportunities.
- Our OviTex PRS products are designed with a patented corner-lock stitch pattern designed to resist deformation and to control the degree and direction of stretching of the product. 13 Table of Contents Our capabilities in polymer science, biologics, textile engineering and analytical testing enable us to quickly design innovative products for development and manufacture.
- The key elements of our strategy include: 18 Table of Contents Our Products Our Technology Platform Our advanced reinforced tissue matrix technology consists of multiple layers of minimally-processed, decellularized extracellular matrix derived from ovine rumen with interwoven polymer fibers in a unique embroidered pattern.
- Trade Secrets We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information.
Partnerships
- In September 2023, we entered into a distribution agreement with Advanced Medical Solutions Limited, a company registered in England, to distribute their LIQUIFIX Hernia Mesh Fixation Devices (LIQUIFIX FIX8™ and LIQUIFIX Precision™).
- In addition, we believe our exclusive manufacturing and long-term supply and license agreement with Aroa (the "Aroa License") creates a 8 Table of Contents competitive advantage by allowing us to secure an exclusive supply of ovine rumen at a low cost.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XGN | Exagen Inc. | USD 4.68 | ▼ 5.26% |
| SIBN | SI-BONE, Inc. | USD 16.62 | ▼ 0.54% |
| APYX | Apyx Medical Corporation | USD 3.92 | ▲ 0.26% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.02 | ▼ 11.93% |
| STRO | Sutro Biopharma, Inc. | USD 22.88 | ▼ 2.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:45 UTC. This page is informational and not investment advice.